Recent Publications


Bekendam RH, Bendapudi PK, Lin L, Nag PP, Pu J, Kennedy DR, Feldenzer A, Chiu J, Cook KM, Furie B, Huang M, Hogg PJ, Flaumenhaft R. A substrate-driven allosteric switch that enhances PDI catalytic activity. Nat Commun 2016; 7:12579.

Bowley SR, Fang C, Merrill-Skoloff G, Furie BC, Furie B. Protein disulfide isomerase secretion following vascular injury initiates a regulatory pathway for thrombus formation. Nat Commun 2017; 8:14151.

Flaumenhaft R, Furie B. Vascular thiol isomerases. Blood 2016; 128:893-901.

Stopa JD, Baker KM, Grover SP, Flaumenhaft R, Furie B. Kinetic-based trapping by intervening sequence variants of the active sites of protein-disulfide isomerase identifies platelet protein substrates. J Biol Chem 2017; 292:9063-74.

Stopa JD, Neuberg D, Puligandla M, Furie B, Flaumenhaft R, Zwicker JI. Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. JCI Insight 2017; 2:e89373.

Gong L, Proulle V, Fang C, Hong Z, Lin Z, Liu M, Xue G, Yuan C, Lin L, Furie BC, Flaumenhaft R, Andreasen P, Furie B, Huang M. A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase. J Cell Mol Med 2016; 20:1851-60.

Kolyada A, Ke Q, Karageorgos I, Mahlawat P, Barrios DA, Kang PM, Beglova N. Soluble analog of ApoER2 targeting beta2-glycoprotein I in immune complexes counteracts hypertension in lupus-prone mice with spontaneous antiphospholipid syndrome. J Thromb Haemost 2016; 14:1298-307.

Lin L, Gopal S, Sharda A, Passam F, Bowley S, Stopa J, Xue G, Yuan C, Flaumenhaft R, Furie BC, Huang M, Furie B. Quercetin-3-rutinoside inhibits protein disulfide isomerase by binding to its b’x domain. J Biol Chem 2015; 290:24543-52.

Schulman S, Bendapudi P, Sharda A, Chen V, Bellido-Martin L, Jasuja R, Furie BC, Flaumenhaft R, Furie B. Extracellular thiol isomerases and their role in thrombus formation. Antioxid Redox Signal 2016; 24:1-15.

Simeoni I, Stephens JC, Hu F, Deevi SV, Megy K, Bariana TK, Lentaigne C, Schulman S, Sivapalaratnam S, Vries MJ, Westbury SK, Greene D, Papadia S, Alessi MC, Attwood AP, Ballmaier M, Baynam G, Bermejo E, Bertoli M, Bray PF, Bury L, Cattaneo M, Collins P, Daugherty LC, Favier R, French DL, Furie B, Gattens M, Germeshausen M, Ghevaert C, Goodeve AC, Guerrero JA, Hampshire DJ, Hart DP, Heemskerk JW, Henskens YM, Hill M, Hogg N, Jolley JD, Kahr WH, Kelly AM, Kerr R, Kostadima M, Kunishima S, Lambert MP, Liesner R, López JA, Mapeta RP, Mathias M, Millar CM, Nathwani A, Neerman-Arbez M, Nurden AT, Nurden P, Othman M, Peerlinck K, Perry DJ, Poudel P, Reitsma P, Rondina MT, Smethurst PA, Stevenson W, Szkotak A, Tuna S, van Geet C, Whitehorn D, Wilcox DA, Zhang B, Revel-Vilk S, Gresele P, Bellissimo DB, Penkett CJ, Laffan MA, Mumford AD, Rendon A, Gomez K, Freson K, Ouwehand WH, Turro E. A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood 2016; 127:2791-803.

Passam FH, Lin L, Gopal S, Stopa JD, Bellido-Martin L, Huang M, Furie BC, Furie B. Both platelet- and endothelial cell-derived ERp5 supports thrombus formation in a laser-induced mouse model of thrombosis. Blood. 2015 Jan 26.

Sharda A, Kim SH, Jasuja R, Gopal S, Flaumenhaft R, Furie BC, Furie B. Defective PDI release from platelets and endothelial cells impairs thrombus formation in Hermansky-Pudlak syndrome. Blood. 2015 Jan 15. 

Schulman S, Furie B. How I treat: poisoning with vitamin K antagonists. Blood 2014 Nov 6. 

Flaumenhaft R, Furie B, Zwicker JI.  Therapeutic Implications of Protein Disulfide Isomerase Inhibition in Thrombotic Disease.  Arterioscler Thromb Vasc Biol. 2014 Aug 7. 

Proulle V, Furie RA, Merrill-Skoloff G, Furie BC, Furie B.  Platelets are required for enhances activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood. 2104 May 13. 

Furie B, Flaumenhaft R. Thiol isomerases in thrombus formation.  Circ Res. 2014 Mar 28; 114(7):1162-73.  

Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med. 2013 Dec 12;369(24):2345-6.  

Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, Mantha S, Kessler CM, Eneman J, Raghavan V, Lenz HJ, Bullock A, Buchbinder E, Neuberg D, Furie B. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).  Br J Haematol. 2013 Feb;160(4):530-7.